High ghrelin and obestatin levels and low risk of developing fatty liver

Annals of Hepatology

Volumn 9, Issue 1, 2010, Pages 52-57

  Gutierrez Grobe, Ylse ^a   Villalobos Blasquez, Israel ^a   Sánchez Lara, Karla ^a   Villa, Antonio R ^b   Ponciano Rodríguez, Guadalupe ^b   Ramos, Martha H ^a   Chavez Tapia, Norberto C ^a   Uribe, Misael ^a   Méndez Sánchez, Nahum ^a  

^a LIVER RESEARCH UNIT   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Ghrelin; Ghrelin obestatin ratio; Nonalcoholic fatty liver disease; Obestatin

Indexed keywords

GHRELIN; GLUCOSE; OBESTATIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PROTECTION; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; CASE CONTROL STUDY; FATTY LIVER; INSULIN RESISTANCE; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; GHRELIN; HUMANS; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 77954587346     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31679-5     Document Type: Article

References (28)

1. Mendez-Sanchez N, Chavez-Tapia NC, Villa AR, et al. Adipo-nectin as a protective factor in hepatic steatosis. World J Gastroenterol 2005; 11: 1737-1741.
2. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998; 27: 1463-1466.
3. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87: 2988.
4. Uribe M, Zamora-Valdes D, Moreno-Portillo M, et al. Hepatic expression of ghrelin and adiponectin and their recep-tors in patients with nonalcoholic fatty liver disease. Ann Hepatol 2008; 7: 67-71.
5. Mendez-Sanchez N, Arrese M, Zamora-Valdes D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 2007; 27: 423-433.
6. Mendez-Sanchez N, Chavez-Tapia NC, Uribe M. Ghrelin and the gastro-hypothalamic axis. Gac Med Mex 2006; 142: 49-58.
7. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495-522.
8. Marchesini G, Pagotto U, Bugianesi E, et al. Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. J Clin Endocrinol Metab 2003; 88: 5674-5679.
9. Barazzoni R, Bosutti A, Stebel M, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2005; 288: E228-E235.
10. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310: 996-999.
11. Lauwers E, Landuyt B, Arckens L, Schoofs L, Luyten W. Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochem Biophys Res Commun 2006; 351: 21-25.
12. Chartrel N, Alvear-Perez R, Leprince J, et al. Comment on Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2007; 315: 766; author reply.
13. Nogueiras R, Pfluger P, Tovar S, et al. Effects of obestatin on energy balance and growth hormone secretion in rodents. Endocrinology 2007; 148: 21-26.
14. Gao XY, Kuang HY, Liu XM, Duan P, Yang Y, Ma ZB. Circulating ghrelin/obestatin ratio in subjects with Helicobac-ter pylori infection. Nutrition 2009; 25: 506-511.
15. Vicennati V, Genghini S, De Iasio R, Pasqui F, Pagotto U, Pasquali R. Circulating obestatin levels and the ghrelin/ obestatin ratio in obese women. Eur J Endocrinol 2007; 157: 295-301.
16. Guo ZF, Zheng X, Qin YW, Hu JQ, Chen SP, Zhang Z. Circulating preprandial ghrelin to obestatin ratio is increased in human obesity. J Clin Endocrinol Metab 2007; 92: 1875-1880.
17. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gas-troenterology 2002; 123: 745-750.
18. Hernandez-Avila M, Romieu I, Parra S, Hernandez-Avila J, Madrigal H, Willett W. Validity and reproducibility of a food frequency questionnaire to assess dietary intake of women living in Mexico City. Salud Publica Mex 1998; 40: 133-140.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Trea-cher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
21. Gauna C, Delhanty PJ, Hofland LJ, et al. Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab 2005; 90: 1055-1060.
22. Granado M, Martin AI, Lopez-Menduina M, Lopez-Calderon A, Villanua MA. GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia. Am J Physiol Endocrinol Metab 2008; 294: E131-E141.
23. Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steato-hepatitis. Obes Surg 2007; 17: 1374-1380.
24. Zhou X, Xue C. Ghrelin inhibits the development of acute pancreatitis and nuclear factor kappaB activation in pancreas and liver. Pancreas 2009; 38: 752-757.
25. Ren AJ, Guo ZF, Wang YK, Lin L, Zheng X, Yuan WJ. Obestatin, obesity and diabetes. Peptides 2009; 30: 439-444.
26. Haider DG, Schindler K, Prager G, et al. Serum retinol-bin-ding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 2007; 92: 1168-1171.
27. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104: 861-867.
28. Gastaldelli A, Kozakova M, Hojlund K, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-1544.